Quantcast
Home > Quotes > HRTX

Heron Therapeutics, Inc. Common Stock (HRTX) Quote & Summary Data

HRTX 
$23.78
*  
0.86
3.49%
Get HRTX Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading HRTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
52
Today's High / Low
$ 24.869 / $ 23.74
Share Volume
1,156,234
50 Day Avg. Daily Volume
841,489
Previous Close
$ 24.64
52 Week High / Low
$ 42.90 / $ 21.25
Market Cap
1,859,159,661
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.34

Intraday Chart

Shares Traded

Share Volume:
1,156,234
50 Day Avg. Daily Volume:
841,489

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.47

Trading Range

The current last sale of $23.78 is 11.91% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.869 $ 42.90
 Low: $ 23.74 $ 21.25

Company Description (as filed with the SEC)

We are a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, our first commercial product, SUSTOL, was approved by the FDA. SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 ("5-HT3") receptor antagonist that utilizes Heron's Biochronomer Technology to maintain therapeutic levels of granisetron for ³5 days.  ... More ...  



Risk Grade

Where does HRTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 24.52
Open Date:
Mar. 22, 2019
Close Price:
$ 23.78
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info